title: Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy.
abstract: We describe a patient with subacute cutaneous lupus erythematosus, widespread pruritic papulosquamous plaques, and hypocomplementemia. Skin biopsy specimens revealed liquefaction degeneration and colloid bodies and dyskeratotic cells in basal and suprabasal layers. An immunofluorescence study revealed deposits of IgG, IgM, and C3 at the dermalepidermal junction in a bandlike pattern, and particulate IgG deposition in the basal and suprabasal layers. Treatment with prednisolone (15 mg/day), chloroquine phosphate (200 mg/ day), cyclosporine (5 mg/kg daily), and gold (10 mg/day) failed to reduce pruritic plaque formation, and pulse methylprednisolone therapy led to only a transient remission. Clinical exacerbations correlated with a decrease in complement levels. The disease was successfully controlled with dapsone (75 mg/day) and prednisolone (25 mg/day).
authors.affiliation: Department of Dermatology, Kanazawa University School of Medicine, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Tsutsui
authors.forename: T
authors.initials: T
authors.lastname: Imai
authors.forename: N
authors.initials: N
authors.lastname: Hatta
authors.forename: H
authors.initials: H
authors.lastname: Sakai
authors.forename: M
authors.initials: M
authors.lastname: Takata
authors.forename: K
authors.initials: K
authors.lastname: Takehara
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D002738:Chloroquine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D003176:Complement C3 / Q000032:analysis; D003165:Complement System Proteins / Q000172:deficiency*; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D011537:Pruritus / Q000188:drug therapy* / Q000473:pathology; D017444:Skin Diseases, Papulosquamous / Q000188:drug therapy / Q000473:pathology
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003176:Complement C3; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; C023676:chloroquine diphosphate; D016572:Cyclosporine; D002738:Chloroquine; D003622:Dapsone; D003165:Complement System Proteins; D011239:Prednisolone; D008775:Methylprednisolone